Cleveland Clinic Avon Hospital
Cleveland Clinic Avon Hospital was paid $11.72M by Medicaid between Jan 2018 and Dec 2024, across 244 billing codes. Its largest line is 99285, emergency room visit (most serious) — 19% of everything it billed.
AVON, OH 44011
Next to other General Acute Care Hospital providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,795 | $387K | |
| 2019 | 6,686 | $324K | |
| 2020 | 8,319 | $474K | |
| 2021 | 18,071 | $913K | |
| 2022 | 26,609 | $1.09M | |
| 2023 | 162,809 | $5.30M | |
| 2024incomplete | 113,557 | $3.23M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 20,239 | 17,682 | $2.27M |
| 96361 | Intravenous infusion, hydration; each additional hour | 17% | 6,943 | 4,915 | $1.93M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 12,594 | 11,837 | $1.22M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.2% | 10,512 | 9,399 | $1.08M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5.9% | 6,489 | 5,721 | $687K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 2,379 | 2,012 | $486K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 2,146 | 1,783 | $445K |
| G0378 | Hospital observation service, per hour | 2.8% | 4,364 | 2,069 | $330K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 999 | 867 | $225K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 2,206 | 1,792 | $222K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 565 | 439 | $183K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 1,042 | 917 | $183K |
232 more codes
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.5% | 1,414 | $181K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.4% | 420 | $161K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.3% | 876 | $155K |
| 76770 | 1.1% | 933 | $133K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.1% | 1,700 | $130K |
| 80053 | Comprehensive metabolic panel | 1.1% | 24,288 | $125K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 966 | $119K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,091 | $98K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 815 | $76K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,211 | $73K |
| 93975 | <1% | 507 | $50K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,336 | $46K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 194 | $40K |
| 76642 | <1% | 367 | $38K | |
| 76536 | <1% | 388 | $37K | |
| 93971 | <1% | 695 | $36K | |
| 70498 | <1% | 208 | $36K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 289 | $33K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,740 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,548 | $29K |
| 71250 | <1% | 365 | $28K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 125 | $26K |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,331 | $26K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,569 | $25K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,271 | $23K |
| 80061 | Lipid panel | <1% | 1,975 | $21K |
| 76830 | Ultrasound, transvaginal | <1% | 544 | $21K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 172 | $20K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 49 | $20K |
| 72100 | <1% | 694 | $18K | |
| 86850 | <1% | 1,050 | $18K | |
| 85027 | <1% | 5,301 | $17K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 711 | $16K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,225 | $16K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,405 | $15K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 71 | $14K |
| 73564 | <1% | 442 | $13K | |
| 82728 | <1% | 897 | $13K | |
| 86140 | <1% | 1,785 | $13K | |
| 82607 | <1% | 757 | $13K | |
| 84439 | <1% | 728 | $13K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 309 | $13K |
| 73630 | <1% | 838 | $13K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,084 | $12K |
| 96367 | <1% | 526 | $12K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 551 | $11K |
| 74018 | <1% | 626 | $11K | |
| 84702 | <1% | 1,963 | $11K | |
| 70491 | <1% | 47 | $11K | |
| 93799 | <1% | 2,655 | $11K | |
| 72131 | <1% | 164 | $10K | |
| 73030 | <1% | 593 | $10K | |
| 93970 | <1% | 96 | $9K | |
| 86900 | <1% | 1,061 | $9K | |
| 83540 | <1% | 985 | $9K | |
| 73130 | <1% | 520 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,271 | $8K |
| 84484 | <1% | 7,366 | $8K | |
| 86780 | <1% | 552 | $7K | |
| 87631 | <1% | 57 | $7K | |
| 83550 | <1% | 978 | $7K | |
| 83735 | <1% | 9,262 | $7K | |
| 86803 | <1% | 401 | $7K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 21 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,469 | $6K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,352 | $6K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 588 | $6K |
| 85610 | <1% | 1,745 | $6K | |
| 73502 | <1% | 390 | $6K | |
| 81001 | <1% | 9,347 | $6K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 57 | $6K |
| 87340 | <1% | 324 | $6K | |
| 74183 | <1% | 37 | $6K | |
| 76857 | <1% | 476 | $5K | |
| A9270 | Non-covered item or service | <1% | 1,276 | $5K |
| 82962 | <1% | 5,556 | $5K | |
| 82570 | <1% | 532 | $5K | |
| 73610 | <1% | 525 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 329 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,129 | $5K |
| 83880 | <1% | 1,589 | $4K | |
| 70486 | <1% | 90 | $4K | |
| 73221 | <1% | 16 | $4K | |
| 86901 | <1% | 1,059 | $4K | |
| 80076 | <1% | 259 | $4K | |
| 73110 | <1% | 335 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 588 | $4K |
| 80069 | <1% | 253 | $3K | |
| 96376 | <1% | 1,952 | $3K | |
| 90715 | <1% | 241 | $3K | |
| 77061 | <1% | 102 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,329 | $3K |
| 83970 | <1% | 123 | $3K | |
| 70496 | <1% | 257 | $3K | |
| 77062 | <1% | 100 | $3K | |
| 85652 | <1% | 675 | $3K | |
| 87077 | <1% | 859 | $2K | |
| 78264 | <1% | 15 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,173 | $2K |
| 82043 | <1% | 346 | $2K | |
| 83690 | <1% | 4,651 | $2K | |
| 81513 | <1% | 13 | $2K | |
| 82784 | <1% | 135 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 446 | $2K |
| 12001 | <1% | 13 | $2K | |
| 84100 | <1% | 581 | $2K | |
| 84403 | <1% | 117 | $2K | |
| 97116 | <1% | 77 | $2K | |
| 82550 | <1% | 520 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 168 | $2K |
| 86706 | <1% | 102 | $2K | |
| 73560 | <1% | 250 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 193 | $1K |
| 73140 | <1% | 61 | $1K | |
| 87505 | <1% | 23 | $1K | |
| 76870 | <1% | 95 | $1K | |
| 86038 | <1% | 47 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 56 | $1K |
| 86480 | <1% | 32 | $1K | |
| 87186 | <1% | 647 | $1K | |
| 83605 | <1% | 1,870 | $1K | |
| 82746 | <1% | 157 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 748 | $977.10 |
| 85730 | <1% | 627 | $967.42 | |
| 77066 | Tomosynthesis, mammo | <1% | 179 | $945.48 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 27 | $910.62 |
| 84481 | <1% | 76 | $888.09 | |
| 74019 | <1% | 14 | $865.67 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 97 | $832.72 |
| 00811 | <1% | 520 | $822.84 | |
| 85379 | <1% | 1,659 | $813.48 | |
| 72050 | <1% | 15 | $778.37 | |
| 97161 | <1% | 124 | $755.21 | |
| 87481 | <1% | 16 | $742.04 | |
| 82077 | <1% | 830 | $727.69 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 29 | $692.94 |
| 81025 | <1% | 4,133 | $681.21 | |
| 99252 | <1% | 28 | $662.18 | |
| 73590 | <1% | 109 | $653.80 | |
| 97802 | <1% | 15 | $649.22 | |
| 84146 | <1% | 26 | $637.01 | |
| 81003 | <1% | 1,877 | $618.16 | |
| 86762 | <1% | 15 | $564.83 | |
| 86308 | <1% | 152 | $551.39 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 46 | $544.39 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,062 | $530.81 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 27 | $517.46 |
| 84153 | <1% | 32 | $512.24 | |
| 88304 | <1% | 221 | $483.84 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,908 | $482.02 |
| 87070 | <1% | 260 | $471.85 | |
| 87040 | <1% | 448 | $420.85 | |
| 83001 | <1% | 15 | $409.54 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 195 | $393.05 |
| 84550 | <1% | 71 | $379.11 | |
| 86704 | <1% | 23 | $366.47 | |
| 99221 | <1% | 14 | $358.60 | |
| 73080 | <1% | 38 | $356.36 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 201 | $344.82 |
| 87205 | <1% | 272 | $319.86 | |
| 99152 | <1% | 134 | $316.02 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 25 | $314.83 |
| 84156 | <1% | 58 | $304.71 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,228 | $301.46 |
| 00731 | <1% | 485 | $287.29 | |
| 83002 | <1% | 14 | $260.96 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 723 | $232.06 |
| 82565 | <1% | 17 | $222.02 | |
| 72128 | <1% | 12 | $192.23 | |
| 83615 | <1% | 35 | $175.15 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,361 | $167.50 |
| J3490 | Unclassified drugs | <1% | 60 | $132.85 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 872 | $117.32 |
| 87493 | <1% | 18 | $114.16 | |
| 76801 | <1% | 28 | $111.79 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 166 | $95.80 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 21 | $93.62 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,305 | $90.72 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,405 | $86.32 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 372 | $83.34 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 522 | $76.24 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,705 | $69.40 |
| 84132 | <1% | 64 | $67.93 | |
| 88342 | <1% | 36 | $64.98 | |
| C1769 | Guide wire | <1% | 390 | $64.58 |
| J1815 | Injection, insulin, per 5 units | <1% | 24 | $54.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 328 | $49.89 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,029 | $45.69 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 279 | $44.40 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 583 | $44.13 |
| 84145 | <1% | 63 | $42.56 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 819 | $38.17 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,342 | $30.72 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 46 | $28.95 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,782 | $24.09 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 666 | $18.91 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 97 | $16.83 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,188 | $16.56 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 121 | $16.48 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 827 | $15.27 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 260 | $14.60 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 246 | $10.50 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 18 | $9.77 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,106 | $9.11 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 549 | $7.66 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 27 | $6.29 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 57 | $5.72 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 30 | $4.07 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 163 | $2.40 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 56 | $0.45 |
| 3078F | 0% | 15 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 566 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 130 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 19 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 13 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 31 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 91 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 65 | $0.00 |
| C2625 | Stent, non-coronary, temporary, with delivery system | 0% | 66 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 13 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 17 | $0.00 |
| 82365 | 0% | 33 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 15 | $0.00 |
| 94760 | 0% | 1,496 | $0.00 | |
| 3074F | 0% | 19 | $0.00 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 485 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 89 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 29 | $0.00 |
| 00813 | 0% | 39 | $0.00 | |
| 82803 | 0% | 55 | $0.00 | |
| 74022 | 0% | 16 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.